Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Piper Sandler upgrades to “overweight” with USD145 target, implying about 18% upside.
  • Mixed broker actions: Raymond James trims target; KeyCorp reiterates overweight with lower target.
  • Consensus sits at “Moderate Buy,” with average price target at USD179 per MarketBeat.

ICU Medical (NASDAQ: ICUI) was upgraded to overweight by Piper Sandler in a Friday report, with a USD145 price target that indicates an estimated 17.92% upside from recent levels, according to MarketBeat. The change reflects a more favorable stance on the company’s near-term risk-reward and earnings trajectory within medical supplies and infusion therapy markets. While the new target marks a cut relative to some earlier Street peaks, it still places shares below the firm’s assessed fair value range.

Recent broker commentary presents a varied picture. On August 8, Raymond James reduced its target from USD187 to USD180 while assigning a strong-buy rating. On April 21, KeyCorp lowered its target from USD209 to USD191 and maintained an overweight rating, indicating confidence in longer-term fundamentals despite valuation and execution considerations. In contrast, Wall Street Zen moved the shares from buy to hold on August 9, citing a more balanced risk profile after earlier gains and estimate revisions.

Across published views tracked by MarketBeat, two analysts rate ICUI hold, three buy, and one strong buy, yielding an overall “Moderate Buy” consensus and an average price target of USD179. Against Piper Sandler’s USD145 marker, the consensus target suggests additional upside potential if execution and margins track analysts’ models.

From a market positioning standpoint, ICU Medical operates across infusion systems, IV consumables, and critical-care disposables. Investor focus remains on integration progress, cost normalization, product cadence, and hospital purchasing trends, all of which influence revenue visibility and margin path. The divergence among targets—USD145 (Piper Sandler), USD180 (Raymond James), and USD191 (KeyCorp)—highlights sensitivity to assumptions around pricing, mix, and operating leverage.